Share This

Public company info - Zhaoke Ophthalmology Limited , 06622.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Zhaoke Ophthalmology Limited, 06622.HK - Company Profile
Chairman Li Xiaoyi
Share Issued (share) 535,000,000
Par Currency U.S. Dollar
Par Value 2.5E-7
Industry Medicine
Corporate Profile Business Summary: The group is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Performance for the year: The group recorded net losses of RMB122.1 million and RMB727.0 million for the years ended December 31, 2019 and 2020. Business Review Leveraging the group’s deep domain expertise, the group have built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. the group have also established an advanced ophthalmic manufacturing facility and are assembling an experienced marketing team in anticipation of near-term product launch. the group’s goal is to become a leader in China and the neighboring ASEAN marketplace. China has a large and underserved ophthalmic patient population. In 2019, the total prevalence of ocular diseases and disorders in China was significantly higher than the United States, yet the ophthalmic pharmaceutical market was only one-sixth as large, according to CIC. This suggests significant growth potential. According to CIC, the Chinese ophthalmic pharmaceutical market is forecast to grow from US$2.6 billion in 2019 to US$20.2 billion in 2030, at a CAGR of 20.6%. However, the market is fragmented, lacking a leader with ophthalmic-focused expertise that can provide a comprehensive solution for this specialty therapeutic area. To address this attractive market opportunity, the group have built an ophthalmic drug pipeline comprising 13 innovative drugs and 12 generic drugs as classified under NMPA drug registration regulations. the group’s innovative pipeline includes 8 drug candidates which have the potential to be market-leading products in China if approved. the group’s generic pipeline includes 6 potential first-to-market generics in China, which the group believe will bring us near-term cash flows and significant first-mover advantages in commercial-scale manufacturing and marketing. According to CIC, the group have one of the most comprehensive ophthalmic drug pipelines in China. In designing the group’s pipeline, the group have initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Most ocular conditions present at variable stages of disease severity, often driven by multiple pathological processes that affect local microenvironments with specific tissue responses. Hence most conditions are heterogeneous in nature. Therefore, for each of the major indications, the group typically develop multiple drug candidates with different mechanisms of action. the group expect the group’s multi-targeted approach to give physicians access to an arsenal of different drugs and the therapeutic flexibility to administer them as mono- or combination therapies, helping them formulate an optimal regimen for each patient and serve a broader group of patients in each of the ophthalmic sub-specialties. Through this pipeline strategy, the group aim to become the essential one-stop solution. The group have developed internal capabilities in key aspects of ophthalmic drug development. the group’s specialized in-house research, development, clinical and regulatory capabilities have enabled us to concurrently advance multiple innovative and generic drug candidates through the preclinical and clinical phases. the group have a solid track record in business development, having in-licensed a number of drug candidates across major indications with high growth potential from international partners. Setting us apart from competitors in China, the group have established a commercial-scale advanced manufacturing facility, which is designed and built for ophthalmic drugs in compliance with cGMP requirements of China, the United States and the European Union. The group is also assembling a commercial team with extensive experience covering various nationwide sales channels and ophthalmologists in China. the group believe these established capabilities will help us bring innovative and comprehensive ophthalmic therapies to market and become the partner of choice of multinational pharmaceutical companies. The group is led by an international management team with decades of industry experience and a track record of research and development, clinical operations, manufacturing, regulatory communications, business development and commercialization of ophthalmic therapies. In addition, the group have received strong endorsement from blue-chip investors, including GIC, Hillhouse, TPG, Loyal Valley Capital, Orbimed and Aier Eye Hospital. Prospects: The group’s goal is to become the leader in the ophthalmic pharmaceutical marketplace in China and the neighboring ASEAN countries. Specifically, the group plan to pursue the following strategies: • build a durable and recognized “Zhaoke Ophthalmology” brand in China and other markets of interest; • establish a track record in innovation by advancing the clinical development, regulatory approval and commercialization of innovative drug candidates; • extend leadership in innovation by rapidly advancing the group’s preclinical- or IND-stage drug candidates through internal research and strategic partnerships; • build marketing infrastructure and momentum by rapidly commercializing generic pipeline; • continue to enhance the group’s fully integrated ophthalmic platform; and • expand the group’s global footprint through organic growth and collaborations.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.